uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding

Core Viewpoint - uniQure N.V. has secured a $175 million non-dilutive senior secured term loan facility with Hercules Capital to enhance financial flexibility for the potential commercial launch of its investigational gene therapy AMT-130 for Huntington's disease [1][2]. Financial Details - The loan facility includes three tranches: a first tranche of $50 million to refinance existing debt, a second tranche of $100 million available upon achieving regulatory and financial milestones, and a third tranche of up to $25 million subject to Hercules' approval [3]. - The interest rate for all tranches is floating, set at the greater of 9.45% or the prime rate plus 2.45%, with a current floating rate of 9.70%, down from a previous rate of 11.95% [3]. Company Background - uniQure is a leader in gene therapy, focusing on transformative therapies for severe medical conditions, including Huntington's disease, refractory temporal lobe epilepsy, ALS, and Fabry disease [5]. - The company has achieved significant milestones, including the approval of its gene therapy for hemophilia B, marking a major advancement in genomic medicine [5]. Partner Information - Hercules Capital is a prominent specialty finance company that provides senior secured venture growth loans to high-growth, innovative companies in technology and life sciences, having committed over $22 billion to more than 680 companies since its inception [6].